908 Devices initiated with an Overweight at Stephens

Stephens analyst Jacob Johnson initiated coverage of 908 Devices with an Overweight rating and $14 price target. The firm, which views process analytics as "one of the key themes in bioprocessing over the next decade," calls it "early innings for the 908 story." 908 ended 2022 with three key offerings, has added to that in 2023 with the launch of Maven, and has another planned product launch this year, noted the firm, which adds that it likes "where 908 is situated from a thematic perspective."